FMFuyuhiko Motoi

Fuyuhiko Motoi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fuyuhiko Motoi has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Megacolon Secondary to Acute Pancreatitis Requiring Differentiation from Chronic Intestinal Pseudo-obstruction—A Case Report—

    by Hideaki Sato, Masaharu Ishida, Munenori Nagao, Fuyuhiko Motoi, Takeshi Naitoh, Michiaki Unno

    症例は28歳の男性で,重症急性膵炎および被包化壊死に対し,経皮的・内視鏡的ドレナージなどの加療を行った既往がある.外来での経過観察中に麻痺性腸閉塞を発症し,当院で入院加療を行った.当初は慢性偽性腸閉塞症(CIPO)が疑われたが,シネMRIで小腸の運動機能は保たれていることが判明し,結腸の運動機能障害を伴う慢性巨大結腸症と診断した.回腸瘻造設術を施行し,その後社会復帰が可能となった.CIPOは小腸を主体とし,食道から大腸までの全消化管に起こり得る消化管運動機能障害で,機械的な閉塞機転がないにもかかわらず腸閉塞様症状を引き起こす疾患である.一方で,慢性巨大結腸症は,以前は結腸型CIPOと呼ばれていたが,外科治療が無効なことが多いCIPOに対し,手術による治療効果が高く,これらの鑑別は非常に重要である.われわれは,本邦において報告例のない急性膵炎に続発した慢性巨大結腸症の治療経験を得たので,ここに報告する.

  • Surgical Outcome of Extra-hepatic Cholangiocarcinoma

    by Michiaki Unno, Kei Nakagawa, Hiroki Hayashi, Koji Fukase, Fuyuhiko Motoi, Takashi Kamei, Takeshi Naitoh

  • Open Access

    A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis

    by Mitsuhiro Shimura, Masamichi Mizuma, Hiroki Hayashi, Akiko Mori, Tomoyoshi Tachibana, Tatsuo Hata, Masahiro Iseki, Tatsuyuki Takadate, Kyohei Ariake, Shimpei Maeda, et al.

    Pancreatic cancer with distant metastases is classified as “unresectable,” for which the standard treatment is systemic chemotherapy. The effectiveness of radical resection for pancreatic cancer with distant metastases is unknown. Here, we report a case of long term survival treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. A 73-year-old man was referred to our hospital to examine and treat for cancer of the pancreatic body. Computed tomography (CT) scan revealed a 26-mm hypovascular tumor in contact with the common hepatic artery (CHA) (> 180°), the celiac artery (< 180°), and portal vein at the pancreatic body. Resectability was determined as “borderline resectable.” Two courses of gemcitabine plus S-1 combination therapy (GS) were administered as neoadjuvant chemotherapy (NAC). CT scan showed tumor shrinkage (21 mm), determined as stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST). Although the abdomen was opened for radical resection, a small nodule on the liver was detected and removed. Since the nodule was diagnosed as adenocarcinoma by intraoperative frozen section, resection of the primary tumor was not performed. After three subsequent courses of GS therapy, no distant metastases were detected under radiological findings. Distal pancreatectomy with celiac artery resection (DP-CAR) was performed as radical surgery 6 months after the initial diagnosis. Histological diagnosis was well-differentiated tubular adenocarcinoma, showing ypT1 ypN1 M1 stage IV, negative surgical margin (R0), and grade III in the Evans classification. S-1 was administered every other day from 6 months after resection up to the present. The patient has been alive with no recurrence for 5 years after the initial diagnosis and 4.5 years after the resection. There is a case that received survival benefits from conversion surgery following chemotherapy after diagnostic metastasectomy in pancreatic cancer with synchronous liver metastasis.


  • Open Access

    Pancreatic neuroendocrine tumor with complete replacement of the pancreas by serous cystic neoplasms in a patient with von Hippel-Lindau disease: a case report

    by Shimpei Maeda, Fuyuhiko Motoi, Shuhei Oana, Kyohei Ariake, Masamichi Mizuma, Takanori Morikawa, Hiroki Hayashi, Kei Nakagawa, Takashi Kamei, Takeshi Naitoh, et al.

    Von Hippel-Lindau disease is a dominantly inherited multi-system syndrome with neoplastic hallmarks. Pancreatic lesions associated with von Hippel-Lindau include serous cystic neoplasms, simple cysts, and neuroendocrine tumors. The combination of pancreatic neuroendocrine tumors and serous cystic neoplasms is relatively rare, and the surgical treatment of these lesions must consider both preservation of pancreatic function and oncological clearance. We report a patient with von Hippel-Lindau disease successfully treated with pancreas-sparing resection of a pancreatic neuroendocrine tumor where the pancreas had been completely replaced by serous cystic neoplasms, in which pancreatic function was preserved. A 39-year-old female with von Hippel-Lindau disease was referred to our institution for treatment of a pancreatic neuroendocrine tumor. Abdominal computed tomography demonstrated a well-enhanced mass, 4 cm in diameter in the tail of the pancreas, and two multilocular tumors with several calcifications, 5 cm in diameter, in the head of the pancreas. There was complete replacement of the pancreas by multiple cystic lesions with diameters ranging from 1 to 3 cm. Magnetic resonance cholangiopancreatography showed innumerable cystic lesions on the whole pancreas and no detectable main pancreatic duct. Endoscopic ultrasound-guided fine-needle aspiration of the mass in the pancreatic tail showed characteristic features of a neuroendocrine tumor. A diagnosis of pancreatic neuroendocrine tumor in the tail of the pancreas and mixed-type serous cystic neoplasms replacing the whole pancreas was made and she underwent distal pancreatectomy while avoiding total pancreatectomy. The stump of the pancreas was sutured as firm as possible using a fish-mouth closure. The patient made a good recovery and was discharged on postoperative day 9. She is currently alive and well with no symptoms of endocrine or exocrine pancreatic insufficiency 8 months after surgery. A pancreas-sparing resection should be considered for patients with pancreatic neuroendocrine tumors and complete cystic replacement of the pancreas to preserve quality of life after surgery.


  • New Reconstructive Procedure after Intestinal Resection for Crohn's Disease: Antimesenteric Cutback End-to-Side Isoperistaltic Anastomosis

    by Kazuhiro Watanabe, Munenori Nagao, Tomoya Abe, Shinobu Ohnuma, Hideaki Karasawa, Fuyuhiko Motoi, Takeshi Naitoh, Michiaki Unno

  • Open Access

    A case of adult undifferentiated embryonal sarcoma of the liver successfully treated with right trisectionectomy: a case report

    by Akiko Mori, Koji Fukase, Kunihiro Masuda, Naoaki Sakata, Masamichi Mizuma, Hideo Ohtsuka, Takanori Morikawa, Kei Nakagawa, Hiroki Hayashi, Fuyuhiko Motoi, et al.


  • Open Access

    Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report

    by Kyohei Ariake, Fuyuhiko Motoi, Masamichi Mizuma, Keigo Murakami, Tatsuyuki Takadate, Hideo Ohtsuka, Koji Fukase, Kunihiro Masuda, Hiroki Hayashi, Kei Nakagawa, et al.

    The prognosis for pancreatic cancer remains dismal because many patients are diagnosed with unresectable cancer at the initial diagnosis. Recently, conversion surgery was reported as an effective treatment for initially unresectable pancreatic cancer with a favorable response to non-surgical treatment lasting over 240 days. Here, we describe a case of locally advanced pancreatic cancer (LAPC) successfully resected after treatment with S-1 and radiation followed by gemcitabine/nab-paclitaxel therapy. A 73-year-old man with LAPC was referred to our hospital. Computed tomography findings revealed a 2.5-cm mass in the pancreatic body that had invaded the celiac artery, common hepatic artery, and splenic artery. Superior mesenteric artery (SMA) encasement was not observed, but tumor abutment over 180° with the main tumor was detected. Staging laparoscopy showed no findings of distant metastasis, and washing cytology revealed no malignancy. He was diagnosed with unresectable pancreatic cancer. Treatment with S-1 with radiation therapy followed by gemcitabine with nab-paclitaxel was performed. Six months after the initial treatment, the tumor size had decreased to 1.2 cm, and encasement of the main artery was diminished. Though abutment to the main artery, including the SMA, was still detected, distal pancreatectomy with celiac artery resection was performed. The histopathological findings around the celiac artery revealed fibrous changes with an Evans classification of grade IIb. There was no residual cancer at the periphery; thus, R0 resection was achieved. The patient has been healthy and without recurrence for more than 12 months since the initial treatment. Gemcitabine/nab-paclitaxel therapy revealed high response rate for metastasic pancreatic cancer (PC), but the effect for LAPC proposing conversion surgery was not well discussed. In this case, we achieve R0 resection combined with chemoradiation therapy and gemcitabine/nab-paclitaxel therapy. This regimen was also effective for LAPC and may be used to increase the population of conversion surgery by its high response rate.


  • Chronological evaluation of postoperative nutritional status and quality of life of pancreatic cancer patients

    by Naoko Sato, Fuyuhiko Motoi, Kyohei Ariake, Kei Nakagawa, Kei Kawaguchi, Masami Sato, Yu Katayose, Fumiko Sato, Michiaki Unno

    【背景】膵癌手術症例では術式が広範囲に及び,術後侵襲,膵外分泌機能の低下,胃・消化管機能の低下などによる栄養不良は患者のQOL低下に影響する可能性がある.【目的】術後膵癌患者の栄養状態とQOLの関連を経時的に明らかにし,QOLの改善を栄養的側面から検討する.【方法】登録患者164例のうち術前/術後3ヶ月/6ヶ月のCONUTによる栄養評価および健康関連QOL尺度SF-36v2によるQOL評価を完了した65例を解析対象とし,栄養状態とQOLの関連を統計学的に検討した.【結果】膵癌患者は術前から栄養不良傾向を認め,術後3ヶ月では全体的に低下した.特にPD,TP群は術後6ヶ月でも改善しなかった.栄養不良は,QOLのうち「身体機能」「日常生活役割機能(身体)」「社会生活機能」の低下と関連した.【結論】栄養障害は患者のQOLの低下に影響する.術後6ヶ月時点での栄養障害の改善がQOL向上の鍵となりうる.


  • A case of mucinous cystic neoplasm of the pancreas with spontaneous rupture

    by Yukie Kyakumoto, Masamichi Mizuma, Masaharu Ishida, Tomoyoshi Tachibana, Masahiro Iseki, Tatsuyuki Takadate, Tomoya Abe, Hideo Ohtsuka, Naoaki Sakata, Takanori Morikawa, et al.


  • Open Access

    Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties

    by Shuichi Aoki, Masamichi Mizuma, Yayoi Takahashi, Yoichi Haji, Ryo Okada, Tomoya Abe, Hideaki Karasawa, Keiichi Tamai, Takaho Okada, Takanori Morikawa, et al.

    Little is known about the roles of Notch signaling in cholangiocarcinoma (CC). The expression of hairy and enhancer of split 1 (Hes-1) has not been investigated yet in resected specimens of CC. Notch signaling has been reported to be related to cancer stem cell (CSC) like properties in some malignancies. Our aim is to investigate the participation of Notch signaling in resected specimens of extrahepatic CC (EHCC) and to evaluate the efficacy of CC cells with CSC-like properties by Notch signaling blockade. First, the expression of Notch1, 2, 3, 4 and Hes-1 was examined by immunohistochemistry in 132 resected EHCC specimens. The clinicopathological characteristics in the expression of Notch receptors and Hes-1 were investigated. Second, GSI IX, which is a γ-secretase-inhibitor, was used for Notch signaling blockade in the following experiment. Alterations of the subpopulation of CD24+CD44+ cells, which are surface markers of CSCs in EHCC, after exposure with GSI IX, gemcitabine (GEM), and the combination of GSI IX plus GEM were assessed by flow cytometry using the human CC cell lines, RBE, HuCCT1 and TFK-1. Also, anchorage-independent growth and mice tumorigenicity in the cells recovered by regular culture media after GSI IX exposure were assessed. Notch1, 2, 3, 4 and Hes-1 in the resected EHCC specimens were expressed in 50.0, 56.1, 42.4, 6.1, and 81.8 % of the total cohort, respectively. Notch1 and 3 expressions were associated with poorer histological differentiation (P = 0.008 and 0.053). The patients with the expression of at least any one of Notch1-3 receptors, who were in 80.3 % of the total, exhibited poorer survival (P = 0.050). Similarly, the expression of Hes-1 tended to show poor survival (P = 0.093). In all of the examined CC cell lines, GSI IX treatment significantly diminished the subpopulation of CD24+CD44+ cells. Although GEM monotherapy relatively increased the subpopulation of CD24+CD44+ cells in all lines, GSI IX plus GEM attenuated it. Anchorage-independent growth and mice tumorigenicity were inhibited in GSI IX-pretreated cells in RBE and TFK-1 (P < 0.05). Aberrant Notch signaling is involved with EHCC. Inhibition of Notch signaling is a novel therapeutic strategy for targeting cells with CSC-like properties.